These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Three new drugs for type 2 diabetes. Drug Ther Bull; 2008 Jul; 46(7):49-52. PubMed ID: 18603639 [TBL] [Abstract][Full Text] [Related]
23. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Herman GA; Stein PP; Thornberry NA; Wagner JA Clin Pharmacol Ther; 2007 May; 81(5):761-7. PubMed ID: 17392725 [TBL] [Abstract][Full Text] [Related]
24. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Deacon CF Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107 [TBL] [Abstract][Full Text] [Related]
25. Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes. Scherbaum WA Diabetes Obes Metab; 2009 May; 11 Suppl 2():1-2. PubMed ID: 19385977 [No Abstract] [Full Text] [Related]
26. Vildagliptin does not affect C-peptide clearance in patients with type 2 diabetes. He YL; Horowitz A; Watson CE; Foley JE; Sallas W; Ligueros-Saylan M J Clin Pharmacol; 2007 Jan; 47(1):127-31. PubMed ID: 17192511 [No Abstract] [Full Text] [Related]
27. Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement. Mest HJ Curr Opin Investig Drugs; 2006 Apr; 7(4):338-43. PubMed ID: 16625820 [TBL] [Abstract][Full Text] [Related]
28. Glucagon-like peptide-1 derivatives and dipeptidyl peptidase-IV inhibitors. New hope for the treatment of type-2 diabetes. Al-Omar MA; Al-Arifi MN Saudi Med J; 2005 Oct; 26(10):1511-5. PubMed ID: 16228047 [TBL] [Abstract][Full Text] [Related]
29. Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes. Prescrire Int; 2008 Oct; 17(97):188. PubMed ID: 19534040 [No Abstract] [Full Text] [Related]
30. Incretin-based therapies in type 2 diabetes: a review of clinical results. Bosi E; Lucotti P; Setola E; Monti L; Piatti PM Diabetes Res Clin Pract; 2008 Dec; 82 Suppl 2():S102-7. PubMed ID: 19022515 [TBL] [Abstract][Full Text] [Related]
31. 3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes. Coumar MS; Chang CN; Chen CT; Chen X; Chien CH; Tsai TY; Cheng JH; Wu HY; Han CH; Wu SH; Huang YW; Hsu T; Hsu LJ; Chao YS; Hsieh HP; Jiaang WT Bioorg Med Chem Lett; 2007 Mar; 17(5):1274-9. PubMed ID: 17194587 [TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. He YL; Wang Y; Bullock JM; Deacon CF; Holst JJ; Dunning BE; Ligueros-Saylan M; Foley JE J Clin Pharmacol; 2007 May; 47(5):633-41. PubMed ID: 17442688 [TBL] [Abstract][Full Text] [Related]
34. DPP-4 inhibitors. A new class of drugs for type 2 diabetes. Marino MT Diabetes Self Manag; 2008; 25(4):60, 62-4. PubMed ID: 18717028 [No Abstract] [Full Text] [Related]
35. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes. Del Prato S Int J Clin Pract Suppl; 2007 Aug; (154):38-48. PubMed ID: 17593276 [TBL] [Abstract][Full Text] [Related]
36. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Idris I; Donnelly R Diabetes Obes Metab; 2007 Mar; 9(2):153-65. PubMed ID: 17300591 [TBL] [Abstract][Full Text] [Related]
37. Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors. Pei Z; Li X; Longenecker K; von Geldern TW; Wiedeman PE; Lubben TH; Zinker BA; Stewart K; Ballaron SJ; Stashko MA; Mika AK; Beno DW; Long M; Wells H; Kempf-Grote AJ; Madar DJ; McDermott TS; Bhagavatula L; Fickes MG; Pireh D; Solomon LR; Lake MR; Edalji R; Fry EH; Sham HL; Trevillyan JM J Med Chem; 2006 Jun; 49(12):3520-35. PubMed ID: 16759095 [TBL] [Abstract][Full Text] [Related]
39. Islet cell function is as interesting as insulin resistance for T2DM treatment options. Göke B Int J Clin Pract Suppl; 2008 Mar; (159):1. PubMed ID: 18269434 [No Abstract] [Full Text] [Related]
40. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]